SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves quarterly results beat expectations and raised guidance, with a large revenue backlog and customer prepayments bolstering the AI-compute demand story and easing some financing concerns. The community reaction is split: bulls see stronger execution and potential short covering, while bears remain focused on heavy debt, interest costs and cash burn; the stocks muted, volatile response drew particular attention.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists Q3 results and outlook are driving attention, with traders focused on improved profitability and recurring Samsung and Micron licensing revenue expected to bolster future quarters. The reaction is mostly bullish, though some question the decline in product sales and are disappointed that the call provided no concrete SK Hynix or Nasdaq-uplisting update; speculation about a Hynix deal remains unconfirmed.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the Nov. 22 FDA decision on Capricors deramiocel application for Duchenne muscular dystrophy; management said the application is in final review and described launch preparations. Many traders read CEO Linda Marbns confident Q3-call remarks as encouraging, while others caution that the outcome remains uncertain given FDA concerns and the applications binary risk.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Scrutiny of CEO Jensen Huang over his relationship with a woman alleged to have ties to Chinese intelligenceand questions about Nvidia chip shipments to Chinais driving concern about governance, export controls, and whether Huang could remain CEO; the allegations have not established that company secrets were compromised. Traders are split between viewing the selloff as an oversold buying opportunity ahead of earnings and fearing further fallout from the investigations and shareholder litigation.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigettis Q3 results missed expectations, particularly on revenue, prompting a sharp selloff and renewed criticism of its high valuation, cash burn, and slow path to commercialization. Some traders remain optimistic about its quantum technology and long-term prospects, but that view is competing with concerns that technical progress and government support have yet to translate into meaningful business growth.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costcos announcement of a large special cash dividend and renewed share-buyback authorization is driving the discussion. Many traders welcome the shareholder payout and are bullish on the stock, while others argue the dividend is not free money and that Costcos valuation remains expensive.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius quarterly results are driving attention: revenue growth, expanding gross margins and raised full-year guidance were offset by an EPS miss and weaker-than-expected adjusted EBITDA, prompting a sharp selloff. Bulls view the reaction as an overreaction to the miss and emphasize the growth outlook, while more cautious traders point to continued losses and near-term risks.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Waves Q3 report is driving the discussion: traders are weighing revenue growth and a sizable backlog against softer bookings, continued losses, and questions about turning orders into revenue, amid a sharp selloff. Bulls point to D-Waves commercial potential and cash reserves, while bears argue its valuation remains stretched and near-term demand is unproven.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Strong Q3 results and another increase to full-year revenue guidance drove a sharp rally in SENS, with traders pointing to accelerating Eversense CGM adoption. The gains then faded, prompting debate between bullish holders who see improving commercial momentum and skeptics citing profit-taking, cash needs, and management or dilution risks.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckins Q3 results and new share-repurchase authorization are driving attention: traders highlight stronger profitability and margins, while debating whether that offsets slowing revenue growth and declining same-store sales. The reaction is split, with some viewing the shares as undervalued and others frustrated by muted price action and the lack of a relisting announcement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure

Equity

After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study. 


STLA Stock Pares Loses: Unveils €190 Billion 2030 Revenue Target 

Stellantis is looking to bring €190 billion in revenue from 2030, compared to €154 billion reported in 2025.


Shell Stock Hits 52-Week High – Here’s Why

Rise in oil prices amid the ongoing conflict in the middle-east has spiked Brent crude and other energy product prices. 


Novo Nordisk To Launch Ozempic Pills Following Flat Growth In Diabetes Segment In 2025

The Ozempic pill will be launched in Q2 2026 and be available in doses 1.5 mg, 4 mg, and 9 mg.


Novo Nordisk Shares Tumble On 2025 Earnings Miss, Weak Sales Forecast And Competition Concerns

The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%.


Why Bitfarms Stock Is Down After Hours?

Keefe Bruyette downgraded Bitfarms to ‘Market Perform’ from ‘Outperform’. 


Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week

Reuters reported on Friday, citing IQVIA data shared by analysts, that Novo’s weight-loss pill was prescribed 18,410 times in the week ended January 16.


BHC Stock Plummets On Failed Liver Cirrhosis Trial: Retail Says ‘Lost Battle But Not The War’

The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.


Novo Nordisk Inks Deal With Canada’s Aspect Biosystems To Find More Diabetes Meds Besides Ozempic

Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration.


Genmab Stock Drops On Mixed Results From Late-Stage Trial Of Lymphoma Drug

Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory diffuse large B-cell lymphoma, the company said.


Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Instead of pursuing the eye drop further in glaucoma, Bausch + Lomb will focus on developing a sustained-release implant version of the same drug candidate for geographic atrophy.&nbsp;</li><li>Clinical trials for that program are expected to begin in 2028.</li><li>Following the BL1107 topical setback, Bausch + Lomb’s most advanced pharmaceutical programs are now the dual-action dry eye drop and BL1332 for ocular pain.&nbsp;</li></ul>&nbsp;Shares of Bausch + Lomb (BLCO) fell 4% after hours on Thursday after the company said that its experimental glaucoma treatment BL1107 failed to improve vision in a mid-stage clinical trial, prompting the company to stop development of the drug as a daily eye drop.<h2 class="st-heading-2">Trial Results</h2>The randomized, double-masked study enrolled 159 patients with glaucoma or high eye pressure. After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores, which measure peripheral vision. Key secondary measures of vision improvement also fell short.The drug, however, did succeed in lowering eye pressure, meeting one secondary goal. Safety results were consistent with earlier studies, with no new concerns identified, the company said.Bausch + Lomb has decided not to move forward with BL1107 as a topical eye drop for glaucoma. The company noted that an earlier, smaller study had shown promising vision improvements, but the larger mid-stage trial did not confirm those findings.<h2 class="st-heading-2">Executives React</h2>“Success in drug development is based on a portfolio, not a single program,” said Yehia Hashad, Executive Vice President of R&amp;D and Chief Medical Officer. “Not every program will succeed, but every study helps us make smarter decisions.”Following the BL1107 topical setback, Bausch + Lomb’s most advanced pharmaceutical programs are now the dual-action dry eye drop and BL1332 for ocular pain, both with data readouts expected in the second half of 2026.Instead of pursuing the eye drop further in glaucoma, Bausch + Lomb will focus on developing a sustained-release implant version of the same drug candidate for geographic atrophy, an advanced form of dry age-related macular degeneration, the company said. Clinical trials for that program are expected to begin in 2028.<h2 class="st-heading-2">How Did BLCO Retail Traders React?</h2>On Stocktwits, retail sentiment around BLCO stock stayed within the ‘neutral’ territory while message volume fell from ‘high’ to ‘normal’ levels.A Stocktwits user dismissed the company pipeline as the “worst.”<stembedurl>https://www.stocktwits.com/TickrTalk0007/message/658547774</stembedurl>Another termed the Thursday announcement a “clean negative readout.”<stembedurl>https://www.stocktwits.com/OttoReed328/message/658705745</stembedurl><a href="https://stocktwits.com/symbol/BLCO">BLCO stock</a> has fallen 2% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-chief-elon-musk-says-anthropic-is-clear-ai-leader-vows-not-to-sabotage-compute-deal-despite-rivalry/cZmYODsR7nC">SpaceX Chief Elon Musk Says Anthropic Is ‘Clear AI Leader’ — Vows Not To Sabotage Compute Deal Despite Rivalry</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of eye health company Bausch Lomb Corporation is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study. 

Bausch + Lomb Corp.

Yes, by year-end

Yes, but not this year

No, he stays as CEO

He steps down on his own

Do you think Jensen Huang will be removed as Nvidia’s ($NVDA) CEO?

Stocktwits

Do you think Jensen Huang will be removed as Nvidia’s (

Feed

News

Sentiment

Fundamentals

Info

DFAX Dimensional ETF Trust - Dimensional World ex U.S. Core Equity 2 ETF

Fundamentals

Latest DFAX News